Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 23, No 28 (October 1), 2005: pp. 6881-6889
© 2005 American Society of Clinical Oncology.
DOI: 10.1200/JCO.20005.14.589
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van Meerbeeck, J. P.
Right arrow Articles by Giaccone, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Meerbeeck, J. P.
Right arrow Articles by Giaccone, G.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada

Jan P. van Meerbeeck, Rabab Gaafar, Christian Manegold, Rob J. Van Klaveren, Eric A. Van Marck, Mark Vincent, Catherine Legrand, Andrew Bottomley, Channa Debruyne, Giuseppe Giaccone

From the University Hospital, Ghent, Belgium; National Cancer Center, Cairo, Egypt; UMC Mannheim, Germany; Erasmus MC, Rotterdam, the Netherlands; University Hospital, Antwerp, Edegem, Belgium; NCIC DC, Ontario, Canada; EORTC DC, Brussels, Belgium; and Free University Medical Center, Amsterdam, the Netherlands

Address reprint requests to Jan P. van Meerbeeck, Thoracic Oncology Unit, University Hospital –7K12IE, De Pintelaan 185, B 9000 Ghent, Belgium; e-mail: jan.vanmeerbeeck{at}ugent.be

PURPOSE: We conducted a phase III trial to determine whether first-line treatment with raltitrexed, a thymidine synthase inhibitor, and cisplatin results in superior outcome compared with cisplatin alone in patients with malignant pleural mesothelioma (MPM).

PATIENTS AND METHODS: Eligible patients with histologically proven advanced MPM, not pretreated with chemotherapy, WHO performance status (PS) 0 to 2, and adequate hematological, renal, and hepatic function were randomly assigned to receive cisplatin 80 mg/m2 IV on day 1, alone (arm A) or combined with raltitrexed 3 mg/m2 (arm B). In patients with measurable disease, response was monitored using the Response Evaluation Criteria in Solid Tumors criteria. Health related quality of life (HRQOL) was measured using the European Organisation for Research and Treatment of Cancer QLQ-C30 and Lung Module (QLQ-LC13).

RESULTS: Two hundred fifty patients were randomized: 80% male; median age, 58 years; and WHO PS, 0, 1, 2 in 25, 62, and 13% of cases, respectively. There were no toxic deaths. The main grade 3 or 4 toxicities observed were neutropenia and emesis, reported twice as often in the combination arm. Among 213 patients with measurable disease, response rate was 13.6% (arm A) versus 23.6% (arm B; P = .056). No difference in HRQOL was observed on any of the scales. Median overall and 1-year survival in arms A and B were 8.8 (95% CI, 7.8 to 10.8) v 11.4 months (95% CI, 10.1 to 15), respectively, and 40% v 46%, respectively (P = .048).

CONCLUSION: A combination of raltitrexed and cisplatin improves overall survival compared with cisplatin alone. This study confirms that a combination of cisplatin and an antifolate is superior to cisplatin alone in patients with MPM, without harmful effect on HRQOL.

Supported by an educational grant by AstraZeneca and by Grants No. 5U10-CA11488-30 through 5U10-CA11488-34 from the National Cancer Institute.

Presented as a late breaking abstract at the 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, June 7, 2004.

The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.

Authors’ disclosures of potential conflicts of interest are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 ChestHome page
M. Ray and H. L. Kindler
Malignant Pleural Mesothelioma: An Update on Biomarkers and Treatment
Chest, September 1, 2009; 136(3): 888 - 896.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
G. P Currie, S. J Watt, and N. A Maskell
An overview of how asbestos exposure affects the lung
BMJ, August 24, 2009; 339(aug24_1): b3209 - b3209.
[Full Text]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
T. R. Tilleman, W. G. Richards, L. Zellos, B. E. Johnson, M. T. Jaklitsch, J. Mueller, B. Y. Yeap, A. A. Mujoomdar, C. T. Ducko, R. Bueno, et al.
Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study.
J. Thorac. Cardiovasc. Surg., August 1, 2009; 138(2): 405 - 411.
[Abstract] [Full Text] [PDF]

Home page
 Anticancer ResHome page
M. RALLI, I. TOURKANTONIS, N. MAKRILIA, E. GKINI, E. KOTTEAS, I. GKIOZOS, N. KATIRTZOGLOU, and K. SYRIGOS
Docetaxel plus Gemcitabine as First-line Treatment in Malignant Pleural Mesothelioma: A Single Institution Phase II Study
Anticancer Res, August 1, 2009; 29(8): 3441 - 3444.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
K. Kawaguchi, H. Murakami, T. Taniguchi, M. Fujii, S. Kawata, T. Fukui, Y. Kondo, H. Osada, N. Usami, K. Yokoi, et al.
Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells
Carcinogenesis, July 1, 2009; 30(7): 1097 - 1105.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
R. A. Stahel, W. Weder, E. Felip, and On behalf of the ESMO Guidelines Working Group
Malignant pleural mesothelioma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
Ann. Onc., May 1, 2009; 20(suppl_4): iv73 - iv75.
[Full Text] [PDF]

Home page
 JCOHome page
A. S. Tsao, I. Wistuba, J. A. Roth, and H. L. Kindler
Malignant Pleural Mesothelioma
J. Clin. Oncol., April 20, 2009; 27(12): 2081 - 2090.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. de Perrot, R. Feld, B.C. J. Cho, A. Bezjak, M. Anraku, R. Burkes, H. Roberts, M. S. Tsao, N. Leighl, S. Keshavjee, et al.
Trimodality Therapy With Induction Chemotherapy Followed by Extrapleural Pneumonectomy and Adjuvant High-Dose Hemithoracic Radiation for Malignant Pleural Mesothelioma
J. Clin. Oncol., March 20, 2009; 27(9): 1413 - 1418.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. D. Ricart, J. D. Berlin, K. P. Papadopoulos, S. Syed, D. W. Drolet, C. Quaratino-Baker, J. Horan, J. Chick, W. Vermeulen, A. W. Tolcher, et al.
Phase I, Pharmacokinetic and Biological Correlative Study of OSI-7904L, a Novel Liposomal Thymidylate Synthase Inhibitor, and Cisplatin in Patients with Solid Tumors
Clin. Cancer Res., December 1, 2008; 14(23): 7947 - 7955.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
T. Yokoyama, H. Osada, H. Murakami, Y. Tatematsu, T. Taniguchi, Y. Kondo, Y. Yatabe, Y. Hasegawa, K. Shimokata, Y. Horio, et al.
YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation
Carcinogenesis, November 1, 2008; 29(11): 2139 - 2146.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
J. P. van Meerbeeck and G. Hillerdal
Screening for Mesothelioma: More Harm than Good?
Am. J. Respir. Crit. Care Med., October 15, 2008; 178(8): 781 - 782.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. G. Tournoy, S. A. Burgers, J. T. Annema, F. Vermassen, M. Praet, M. Smits, H. M. Klomp, J. P. van Meerbeeck, and P. Baas
Transesophageal Endoscopic Ultrasound with Fine Needle Aspiration in the Preoperative Staging of Malignant Pleural Mesothelioma
Clin. Cancer Res., October 1, 2008; 14(19): 6259 - 6263.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
K. Nakagawa, K. Yamazaki, H. Kunitoh, T. Hida, K. Gemba, T. Shinkai, Y. Ichinose, S. Adachi, Y. Nambu, N. Saijo, et al.
Efficacy and Safety of Pemetrexed in Combination with Cisplatin for Malignant Pleural Mesothelioma: A Phase I/II Study in Japanese Patients
Jpn. J. Clin. Oncol., May 1, 2008; 38(5): 339 - 346.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Jassem, R. Ramlau, A. Santoro, W. Schuette, A. Chemaissani, S. Hong, J. Blatter, S. Adachi, A. Hanauske, and C. Manegold
Phase III Trial of Pemetrexed Plus Best Supportive Care Compared With Best Supportive Care in Previously Treated Patients With Advanced Malignant Pleural Mesothelioma
J. Clin. Oncol., April 1, 2008; 26(10): 1698 - 1704.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. A. Janne, G. R. Simon, C. J. Langer, R. N. Taub, A. Dowlati, P. Fidias, M. Monberg, C. Obasaju, and H. Kindler
Phase II Trial of Pemetrexed and Gemcitabine in Chemotherapy-Naive Malignant Pleural Mesothelioma
J. Clin. Oncol., March 20, 2008; 26(9): 1465 - 1471.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
R. M. Flores, H. I. Pass, V. E. Seshan, J. Dycoco, M. Zakowski, M. Carbone, M. S. Bains, and V. W. Rusch
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: Results in 663 patients
J. Thorac. Cardiovasc. Surg., March 1, 2008; 135(3): 620 - 626.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
B. Castagneto, M. Botta, E. Aitini, F. Spigno, D. Degiovanni, O. Alabiso, M. Serra, A. Muzio, R. Carbone, R. Buosi, et al.
Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM)
Ann. Onc., February 1, 2008; 19(2): 370 - 373.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
H. L. Kindler, R. Bueno, and J. R. Testa
New Biomarkers, Surgical Controversies, and Rationally Targeted Therapies for Malignant Mesothelioma
ASCO Educational Book, January 1, 2008; 2008(1): 354 - 361.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Bottomley, C. Coens, F. Efficace, R. Gaafar, C. Manegold, S. Burgers, M. Vincent, C. Legrand, and J. P. van Meerbeeck
Symptoms and Patient-Reported Well-Being: Do They Predict Survival in Malignant Pleural Mesothelioma? A Prognostic Factor Analysis of EORTC-NCIC 08983: Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma
J. Clin. Oncol., December 20, 2007; 25(36): 5770 - 5776.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Bottomley and N. K. Aaronson
International Perspective on Health-Related Quality-of-Life Research in Cancer Clinical Trials: The European Organisation for Research and Treatment of Cancer Experience
J. Clin. Oncol., November 10, 2007; 25(32): 5082 - 5086.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
British Thoracic Society Standards of Care Committ
BTS statement on malignant mesothelioma in the UK, 2007
Thorax, November 1, 2007; 62(Suppl_2): ii1 - ii19.
[Full Text] [PDF]

Home page
 Ann OncolHome page
W Weder, R. Stahel, J Bernhard, S Bodis, P Vogt, P Ballabeni, D Lardinois, D Betticher, R Schmid, R Stupp, et al.
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma
Ann. Onc., July 1, 2007; 18(7): 1196 - 1202.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
G. L. Ceresoli, C. Gridelli, and A. Santoro
Multidisciplinary Treatment of Malignant Pleural Mesothelioma
Oncologist, July 1, 2007; 12(7): 850 - 863.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. L. Garland, C. Rankin, D. R. Gandara, S. E. Rivkin, K. M. Scott, R. B. Nagle, A. J.P. Klein-Szanto, J. R. Testa, D. A. Altomare, and E. C. Borden
Phase II Study of Erlotinib in Patients With Malignant Pleural Mesothelioma: A Southwest Oncology Group Study
J. Clin. Oncol., June 10, 2007; 25(17): 2406 - 2413.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
P. N. Chhajed, F. Baty, M. Pless, S. Somandin, M. Tamm, and M. H. Brutsche
Outcome of Treated Advanced Non-small Cell Lung Cancer With and Without Central Airway Obstruction
Chest, December 1, 2006; 130(6): 1803 - 1807.
[Abstract] [Full Text] [PDF]

Home page
 DTBHome page
Can {blacktriangledown}pemetrexed help in malignant mesothelioma?
DTB, October 1, 2006; 44(10): 77 - 80.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. P. van Meerbeeck and A. Bottomley
In Reply
J. Clin. Oncol., October 1, 2006; 24(28): 4667a - 4668.
[Full Text] [PDF]

Home page
 JCOHome page
J. Francart, C. Legrand, R. Sylvester, M. Van Glabbeke, J. P. van Meerbeeck, and A. Robert
Progression-Free Survival Rate As Primary End Point for Phase II Cancer Clinical Trials: Application to Mesothelioma--The EORTC Lung Cancer Group
J. Clin. Oncol., July 1, 2006; 24(19): 3007 - 3012.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. Flynn, R. W. Berg, T. Wong, M. van Aken, M. D. Vincent, M. Fukushima, and J. Koropatnick
Therapeutic potential of antisense oligodeoxynucleotides to down-regulate thymidylate synthase in mesothelioma.
Mol. Cancer Ther., June 1, 2006; 5(6): 1423 - 1433.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. L. Ceresoli, P. A. Zucali, A. G. Favaretto, F. Grossi, P. Bidoli, G. Del Conte, A. Ceribelli, A. Bearz, E. Morenghi, R. Cavina, et al.
Phase II Study of Pemetrexed Plus Carboplatin in Malignant Pleural Mesothelioma
J. Clin. Oncol., March 20, 2006; 24(9): 1443 - 1448.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Bottomley, R. Gaafa, C. Manegold, S. Burgers, C. Coens, C. Legrand, M. Vincent, G. Giaccone, and J. Van Meerbeeck
Short-Term Treatment-Related Symptoms and Quality of Life: Results From an International Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study
J. Clin. Oncol., March 20, 2006; 24(9): 1435 - 1442.
[Abstract] [Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2005 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online